University of Maryland

Oral paratyphoid vaccine enters human trials

The University of Oxford has started recruiting for a Phase 1/2 human challenge trial of a paratyphoid vaccine candidate, the university announced last week. The University of Maryland School of Medicine developed the oral candidate (CVD 1902) to protect against Salmonella Paratyphi infection, per the press release.

An Oxford researcher commented that a licensed paratyphoid vaccine is “desperately needed” due to “increasing antibiotic resistance.”

Mentions:
paratyphoid, vaccines, AMR, Oxford University, University of Maryland, clinical trials
Read more
Covid-19 development round-up: June 5, 2020


The state of the hunt: 

Gavi launched an advance market commitment for Covid-19 vaccines with a $2 billion funding target. Gavi also kicked off a worldwide pooled procurement mechanism for coronavirus vaccines. CEPI announced an investment of up to $383 million in a partnership with AstraZeneca to support manufacturing of the company’s vaccine candidate for distribution by the Gavi-led procurement facility.

 

Vaccines

Existing candidates:
 
The…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Gavi, AstraZeneca, CEPI, SII, Lemann Foundation, NIAID, Moderna, BARDA, Lonza, CSL, University of Queensland, J&J, Merck, Pfizer, CNBG, Inovio, Novavax, AGC Biologics, WRAIR, Rottapharm, Takis, ImmunityBio, NantKwest, Heat Biologics, Chimeron Bio, George Mason University, Codiac Bio, Ragon Institute, iBio, Smorodintsev, Institute of Experimental Medicine, Nanolek, CanSino, Emergent, Lilly, AbCellera, Gilead, TFDA, Genentech, Roche, AbbVie, Harbour BioMed, CalciMedica, I-Mab, Celltrion, BerGenBio, UCB, Sun Pharma, Organicell, NIH, SEEK Group, RDIF, WHO, Sanofi, Cambridge, Siemens Healthineers, University of Maryland, CDC
Read more
Subscribe to University of Maryland